☢️ Amid constant shelling of Ukrainian nuclear power plants and threats from the Kremlin regarding the use of nuclear weapons, Ukraine has begun actively preparing for potential radiation disasters. For the first time, the country signed a contract with the Israeli biotechnology company Pluri, which will supply the drug PLX-R18 — a unique remedy for acute radiation exposure.
Source: PRYAMYI
🤝 The agreement was signed in cooperation with the Ukrainian Hemafund umbilical cord blood bank. The PLX-R18 drug is based on cells obtained from a single placenta and has already shown effectiveness in animal models — survival rates after radiation exposure increase from 29% to 97%.
🧊 Ukraine will receive at least 12,000 doses, enough to assist 6,000 individuals. The drug will be stored in cryopreservation and will be available in case of an emergency.
🧪 The FDA (USA) has granted PLX-R18 “Orphan Drug” status, and research is supported by the U.S. National Institutes of Health.
📢 “We want to be ready. This is not panic — this is strategy,” said Hemafund founder Yaroslav Issakov. This is a clear signal that Ukraine is taking the potential nuclear threat from russia seriously.
Discussion about this post